3 / 32
TRATAMIENTO SISTÉMICO DEL CCRm.
Primera línea
Estudio
N
RG (%)
SLP (meses)
SG (meses)
Sunitinib
vs.
IFNα
750
47
vs.
12
11.0
vs.
5.0
p<0.001
26.4
vs.
21.8
p=0.051
AVOREN
Bevacizumab + IFNα
vs.
IFNα + placebo
649
31
vs.
12
10.4
vs.
5.5
p<0.0001
23.3
vs.
21.3
p=0.1291
CALGB 90206
Bevacizumab + IFNα
vs.
IFNα
732
25.5
vs.
13.1
8.4
vs.
4.9
p<0.0001
18.3
vs.
17.4
p=0.069
VEG105192
Pazopanib
vs.
placebo
233
32
vs.
3
11.1
vs.
2.8
p<0.00001
NA
COMPARZ
Pazopanib
vs.
sunitinib
1100
31
vs.
25
10.5
vs.
10.2
NS
28.4
vs.
29.3
NS
ARCSS
Temsirolimus
vs.
IFNα
626
8.6
vs.
4.6
3.8 vs. 1.9
p<0.001
10.9
vs.
7.3
p=0.008
Motzer RJ, et al. N Engl J Med 2007; 356(2):115.
Escudier B, et al. Lancet 2007;370:2103.
Rini BI, et al. J Clin Oncol 2008;26(33):5422.
Sternberg CN, et al. J Clin Oncol 2010;28(6):1061.
Motzer RJ, et al. N Engl J Med 2013;369(8):722.
Hudes G, et al. N Engl J Med 2007;356:115.